Introduction 648 JPET #56705 6 cDNA for the 407-amino acid TPβ was isolated from a vascular endothelial library (Raychowdhury et al., 1994) . The receptors have been shown to have different C-tails which are likely to play a role in G-protein-coupling specificity and different desensitization characteristics (Hirata et al., 1996) .
The TP receptor is abundantly expressed at both the mRNA and protein level in tissues of relevance to TXA 2 biology, such as platelets, vascular and uterine smooth muscle, uterus and placental tissue, endothelium, epithelium, trophoblasts, thymus, liver and small intestine with TPα expression predominating in most tissues examined (Miggin and Kinsella, 1998) . There is evidence that mRNA for both isoforms is coexpressed in platelets, endothelial cells and a number of other cell/tissue types with significantly greater levels of TPα than TPβ expressed. Isoform selective antibodies permitted detection of TPα, but not TPβ, in human platelets, leading to the suggestion that TPα may be the predominant isoform in platelets, despite the presence of mRNA for both isoforms in these cells (Miggin and Kinsella, 1998) .
TP receptors have also been cloned from K562 cells, HEL cells, endothelial cells, mouse lung, rat kidney and rat astrocytes (Namba et al., 1992; D'Angelo et al., 1994;  JPET #56705
Green monkey kidney cell line that has been used extensively for the transient expression of cloned receptors (Becker et al., 1998) and can produce desirable expression efficiency.
Hepoxilins are hydroxy epoxide metabolites of arachidonic acid formed via the 12-lipoxygenase pathway (Pace-Asciak et al., 1995) . We have previously shown that the hepoxilins possess a variety of biological actions in vitro as well as in vivo; namely, they cause the release of intracellular calcium from calcium stores in human neutrophils (Dho et al., 1990; Laneuville et al., 1993) , and the release of insulin from pancreatic beta cells in vitro (Pace-Asciak and Martin, 1984) and into the circulation of rats in vivo (PaceAsciak et al., 1999) . Since the native hepoxilins are rather unstable, we prepared a series of chemically stable analogs for in vivo use (Demin and Pace-Asciak, 1993) . During more comprehensive screening for in vitro biological actions, we discovered that one of these analogs, PBT-3, potently inhibited collagen-evoked aggregation of human platelets (Pace-Asciak et al., 2002 ).
The present study was designed to further investigate PBT-3 binding to TP receptor isoforms transiently expressed in COS-7 cells. Our results demonstrate significant selectivity of PBT-3 to the TPα isoform which is the isoform most abundant in human platelets.
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Methods
Materials. PBT-3 was prepared in our laboratory as previously described (Demin and Pace-Asciak, 1993 Platelet labeling and stimulation. Platelets were prepared as described above. antibody was used at 1:2,000 dilution. Bound antibodies were detected using enhanced chemiluminescence (ECL) kit and exposed to Hyperfilm.
Autoradiography and densitometric analysis. The above membrane exposed to ECL was kept in strong light overnight to eliminate the chemiluminescence, then it was exposed to Hyperfilm at -70 °C for autoradiography. The intensity of the autoradiograph bands was analyzed using FluorChem software. The areas were integrated using the same program, and the results were expressed in arbitrary units as % of control (untreated) bands. ] i release evoked by collagen (see Table 1 ). M for SQ 29,548 and I-SAP respectively (see Table 1 ). These results show that PBT-3 is about one-tenth less active as an antagonist of I-BOP evoked [Ca 2+ ] i release than SQ 29,548 or I-SAP.
1B. Effects on I-BOP

PBT-3 Inhibits Phosphorylation of Pleckstrin.
2A. Effects of Collagen: Collagen caused the incorporation of [
32 P] into a P47 protein (pleckstrin) in human platelets. A reduction in [ 32 P] incorporation took place in the presence of ASA indicating that pleckstrin phosphorylation followed TP receptor activation by the endogenous thromboxane formed during collagen challenge (Fig. 2) .
PBT-3 blocked the collagen-evoked phosphorylation, both in the presence and absence of ASA. Fig. 2A shows an autoradiogram of newly formed phosphorylated proteins separated on 12% SDS-PAGE gel, with total pleckstrin protein (a measure of loading) being detected by a rabbit anti-human pleckstrin-selective antibody (bottom panels).
Since the collagen effect is a thromboxane mediated event, the presence of ASA reduced the incorporation of [ 32 P] into phosphorylated pleckstrin (P47) as shown by comparing the left panels with the right panels. PBT-3 blocks this event quite well. Note that pleckstrin expression did not change by the various treatments, only the extent of newly phosphorylated pleckstrin did (x-ray film). The inhibitory actions of PBT-3 were dose dependent ( Fig. 3) within the concentration range of 0.06 to 6 µM. The IC 50 value was estimated to be 3 x 10 -7 M (see Table 1 ).
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 4, autoradiogram, top panel, A) . PBT-3 effectively blocked this phosphorylation within the tested concentration range of 0.0006 to 6 µM. The expression levels of the P47 phosphorylated pleckstrin protein were unchanged by the various treatments (Fig. 4, lower panel, B) as determined by western blot analysis and densitometry. The IC 50 value is estimated to be 1 x 10 -8 M (see Table 1 ). were noted to have good clinical efficacy in patients with thrombotic disorders (Keith et al., 1994; Neirotti et al., 1994) . Terbogrel exhibits an equipotent (IC 50 of about 10 nM) activity as TXA 2 synthase inhibitor and TP receptor antagonist (Muck et al., 1998) 
Inhibition of binding by PBT-3 of [
